Anti-Angiogenesis

Phase I Clinical Trial Initiated

Published in Cancer Weekly, January 16th, 2001

OSI Pharmaceuticals, Inc. (OSIP), Uniondale, New York, announced that Pfizer Inc. (PFE) has opened an IND for Phase I clinical trials in the United States to evaluate a small molecule anticancer drug designed to inhibit angiogenesis.

"This is the third drug candidate arising from our successful long term cancer drug discovery alliance with Pfizer to enter clinical trials," stated Colin Goddard, PhD, OSI Pharmaceuticals, Inc. "Moving forward we will continue our focus on the discovery and development of promising small molecule candidates, that are directed against specific gene targets involved in major disease areas including cancer."

The compound...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-01-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry